Drug delivery technology developer Cure Pharmaceutical (OTC:CURR) announced today that it launched two new clinical development programs.
Oxnard, Calif.-based Cure’s first new launch is an antiviral clinical development program for loading a known active pharmaceutical ingredient (API) onto its Curefilm patented drug delivery platform that optimizes the absorption and metabolism of therapeutic devices, according to a news release.
The second pipeline product addition uses a similar approach as the company is set to formulate the delivery of a known anti-seizure API for both adult and pediatric indications. Both programs are slated to develop orally bioavailable products as the company builds toward a specialty pharmaceutical pipeline.
Cure has also recently initiated pharmacokinetics (PK)/bioequivalence studies in support of an FDA investigational new drug application for its Sildenafil Citrate oral dispersable product known as Curefilm Blue.
“We are leveraging our validated drug technology platform, currently in use in a variety of consumer markets as well as our Curefilm Blue clinical program, to enhance shareholder value via this pipeline expansion,” Cure CEO Rob Davidson said in the release. “As we looked to expand our pharmaceutical pipeline, we used a very methodical approach to product selection, striving to best differentiate ourselves as a pharmaceutical researcher and product developer. By working with known APIs and applying them using our Cureform platform, similar to how we have approached our Sildenafil program, we amplify our market opportunities in an important and relevant way by increasing the probability of approval and speed to market.”
